近日,信达生物制药集团宣布旗下产品玛仕度肽注射液的第二项适应症获国家药品监督管理局(NMPA)批准,用于成人2型糖尿病患者的血糖控制。玛仕度肽注射液是全球首个获批的用于2型糖尿病的GCG/GLP-1双受体激动剂。GCG/GLP-1双受体激动剂在GLP-1受体激动剂的基础上激动GCG受体,同时改善胰岛素分泌不足和胰岛素抵抗两大糖尿病核心致病机制,帮助糖尿病患者更好地控制血糖。本次获批主要基于两项...
Source Link近日,信达生物制药集团宣布旗下产品玛仕度肽注射液的第二项适应症获国家药品监督管理局(NMPA)批准,用于成人2型糖尿病患者的血糖控制。玛仕度肽注射液是全球首个获批的用于2型糖尿病的GCG/GLP-1双受体激动剂。GCG/GLP-1双受体激动剂在GLP-1受体激动剂的基础上激动GCG受体,同时改善胰岛素分泌不足和胰岛素抵抗两大糖尿病核心致病机制,帮助糖尿病患者更好地控制血糖。本次获批主要基于两项...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.